<DOC>
	<DOCNO>NCT00225394</DOCNO>
	<brief_summary>CMV viral disease negatively affect transplant patient . CMV prevalent infection transplant patient 3 month drug regimens prevent virus mostly unsuccessful , usually drug stop , patient develop viral disease . Extended use anti-viral drug may , fact , may lead development resistant virus . We hypothesize extend use ( 12 month ) valganciclovir ( Valcyte™ ) efficacious associate development resistant CMV . Sample Size : 100 patient 3 site enrol Patient Selection : Adult ( &gt; 18 year ) recipient cadaveric live donor kidney , pancreas , combine kidney-pancreas transplant . Immunosuppression : To determine accord center ’ standard protocol ( ) . Study Drug : Valcyte™ Days 0 – 90 : All Patients , 900 mg QD Days 91 – 365 : Group 1 : 900 mg QD Group 2 : 450 mg QD Assessment Valgancicovir ( Valcyte™ ) Resistant CMV : Serial serum sample ( transplant , 6 week , 3 , 6 , 9 12 month post-transplant ) PCR amplification DNA sequence analysis detectable CMV identify presence mutation within UL97 UL54 gene . Other Analyses : Additional information evaluate relate development CMV disease , development ganciclovir toxicity , graft rejection graft loss patient death . Preliminary information regard predictive value DNA assay development CMV disease evaluate .</brief_summary>
	<brief_title>Long Term Use Valganciclovir Prophylaxis CMV Disease Kidney Pancreas Transplant Patients</brief_title>
	<detailed_description>CMV infection occur frequently first three month follow transplantation follow treatment acute rejection ; instance relate relatively high level immunosuppression relative stable long-term allograft recipient . Disease occur manifest fever , low white blood cell count , pneumonitis , gastroenteritis , hepatitis , retinitis , multitude symptom . Ganciclovir , potent inhibitor herpesviridae DNA polymerase encode unique long ( UL54 ) region CMV genome , significant impact prophylaxis treatment CMV infection transplant patient . CMV-infected cell produce phosphotransferase , kinase ( UL97 region ) phosphorylates ganciclovir ganciclovir-triphosphate . The triphosphate product inhibits CMV replication competitively inhibit incorporation deoxyguanine triphosphate ( dGTP ) DNA region encode polymerase ( UL54 region ) , thus result premature termination viral DNA synthesis . Resistance ganciclovir confer mutation occur UL97 region CMV genome . Ganciclovir available either oral intravenous formulation . The obvious advantage oral formulation somewhat offset fact bioavailability 8 10 % . The product reformulate addition L-valyl ester ; result compound , valganciclovir ( Valcyte™ ) metabolize ganciclovir 3 7 fold increase bioavailability able maintain serum concentration equivalent intravenous formulation . This provide convenient method obtain therapeutic concentration ganciclovir extend period time without need in-dwelling intravenous line . The optimal length treatment establish relapse rate high 25 % common upon cessation antiviral agent.6 Patients CMV disease initially treat intravenous ganciclovir two week , oral agent many week thereafter . Current laboratory technology allow detection active viral replication , either detection pp65 antigen surface infect leukocyte use PCR amplification detection viral DNA . It however , still unclear whether best therapeutic option treat symptom disappear treat evidence active viral replication cease . The question whether prolonged exposure ganciclovir result increase incidence resistant CMV strain answer . There also theoretical increase risk selection pressure resistant CMV low dose valganciclovir ( 450 mg ) use . This proposal document emergence ganciclovir-resistant strain CMV high-risk kidney , pancreas , combine kidney/pancreas transplant patient receive long-term suppressive therapy Valcyte™ also address issue selection pressure randomize low high dose valganciclovir prophylaxis . Emergence resistance define detection resistance-conferring mutation UL97 ( phosphotransferase ) UL54 ( DNA polymerase ) open reading frame detectable CMV . Objectives Primary To document : 1 . The emergence ganciclovir-resistant CMV PCR amplification DNA sequence analysis detect resistance-conferring mutation UL97 and/or UL54 open reading frame . 2 . The development time-to-onset CMV disease Secondary To document : 1 . The development ganciclovir toxicity 2 . Loss kidney and/or pancreas graft function 3 . Patient death Tertiary To attempt determine predictive value DNA assay development CMV disease . Study Design This phase 4 , 4 center , randomize pilot study . Kidney , pancreas combine kidney/pancreas transplant patient receive induction anti-thymocyte globulin OKT3 and/or either seropositive CMV receive graft CMV seropositive donor receive Valcyte™ 900 mg daily 90 day . Patients randomize either 450 mg 900 mg Valcyte™ day day 91 365 . Patients serially monitor development ganciclovir-resistant CMV . Patients receive standard immunosuppression , antibacterial antifungal prophylaxis , necessary medication determine physician . Statistical Analysis Primary Endpoints : Time development CMV disease emergence ganciclovir-resistant CMV . Methods : Kaplan-Meier product limit estimate median time CMV disease treatment group use , Kaplan-Meier survival curve plot compare treatment difference . Kaplan-Meier product limit estimate median time CMV resistance treatment group use , Kaplan-Meier survival curve plot compare treatment difference . In addition , Cox regression perform compare treatment group use treatment covariate model . Secondary Endpoints : Incidence ganciclovir toxicity , loss kidney and/or pancreas , patient death . Methods : Cox regression perform compare treatment group use treatment incidence resistance covariates model . Fisher ’ exact test use analyze loss kidney and/or pancreas allograft function , patient mortality . Toxicity within two prophylaxis cohort compare use Fisher ’ exact test , also . Tertiary Endpoint : Efficacy DNA assay predict CMV disease . Method : A two-tailed test comparison use test hypothesis high copy number CMV DNA correlate development CMV disease . Additionally , test base Cox proportional hazard model use assess variable impact development CMV resistance relationship copy number DNA . The parameter assess three time points…6 month initiation trial , 12 month post enrollment patient , 24 month post-enrollment . Materials Methods Definitions CMV CMV Infection CMV infection define isolation identification CMV site ( blood , urine , sputum , stool ) , positive seroconversion ( presence positive CMV IgM four-fold increase titer CMV IgG ) , evidence CMV viral replication ( pp65 antigenemia positive CMV PCR amplification technique ) absence clinical symptom . CMV Syndrome CMV syndrome define virologically confirm illness follow : fever , pneumonia , leukopenia , lymphocytosis , thrombocytopenia , serum alanine aminotranferase level &gt; 2.5 x normal , without “ flu–like ” manifestation viral immunity ( malaise , myalgia , arthralgia , anorexia , nausea , vomit ) . Any patient presenting sign symptom time study blood , body fluid , and/or biopsy specimen send viral confirmation may include follow study : histology presence inclusion body , immunofluorescence antibody pp65 antigen qualitative presence CMV genome PCR amplification . CMV Disease CMV disease define CMV infection syndrome following : evidence host cellular viral inclusion biopsy body fluid cytology , positive conventional viral culture CMV , positive “ rapid antigen ” test presence pp65 antigen cell surface buffy coat leukocytes , qualitative presence CMV DNA analyze PCR amplify virus . Specimens use diagnostic procedure may include blood , liver lung biopsy , endoscopic mucosal biopsy brushing , bronchoalveolar lavage , cerebrospinal fluid . Severe CMV Disease Severe CMV disease define CMV disease two organs one following : CMV pneumonia , CMV retinitis , CMV CNS involvement , invasive fungal parasitic disease association CMV infection sort . CMV Mortality CMV mortality define death due symptomatic CMV disease death opportunistic infection evidence CMV disease ongoing CMV viral replication . Ganciclovir Resistant CMV Ganciclovir resistant CMV define detection resistance-conferring mutation UL97 and/or UL54 open reading frame DNA sequence analysis PCR amplify CMV genome . Valganciclovir ( Valcyte™ ) Valcyte™ product Roche Laboratories , Nutley , New Jersey . Patients receive 450 900 mg per day depend stage study individual ’ randomization . Dosage adjust renal insufficiency per package insert . If creatinine clearance ( crcl ) &gt; 60 ( ml/min ) , adjustment need . If crcl 40-59 , patient receive 450 mg daily . Therefore , randomize 900mg/day cohort receive 450 mg randomize receive 450 mg/day receive 450 mg every day ( QOD ) . If creatinine clearance le 40 never improve , patient exclude terminate study . Immunosuppression Immunosuppressive medication administer accord protocols place participate center . The choice maintenance immunosuppression treatment rejection discretion center ’ principal investigator . Concomitant Anti-infectives Patients enrol study receive anti-bacterial anti-fungal prophylaxis determine protocol place transplant organ transplant center . The use antibiotics anti-fungals treatment disease discretion individual patient ’ physician . Hematopoietic Growth Factors Regrastim ( GM-CSF ) ( Prokine® Hoechst-Roussel , Leukine® , Immunex ) filgrastim ( G-CSF ) ( Neupogen® , Amgen ) may use discretion physician treatment leukopenia , include ganciclovir-related leukopenia .</detailed_description>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>1 ) Age great 18 year 2 ) WBC great 2000/mm3 ANC great 500/mm3 3 ) Platelet count great 50,000/mm3 4 ) Hematocrit great 24 5 ) Life expectancy great 1 year determine investigator 6 ) Females must negative pregnancy test sexual partner must also agree practice barrier and/or hormonal method birth control participate study 90 day . Females must agree pregnancy test menstrual cycle miss , positive , must report . 1 . Patients receive systemic therapy acute opportunistic infection time enrollment 2 . Patients receive investigational drug 3 . Patients malignancy within last 5 year exception excise basal squamous cell skin cancer 4 . Patients active substance abuse condition would impair compliance 5 . Patients unable give inform consent 6 . Any patient creatinine clearance &lt; 40 delay graft function posttransplant ATN completely resolve , patient deem prospect improvement creatinine clearance ( &gt; 40 ) would occur resolve ATN . 7 . Persistent ANC &lt; 1,000 2 consecutive week despite treatment GCSF 8 . Any female patient plan become pregnant within one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>CMV</keyword>
	<keyword>Kidney Transplant</keyword>
	<keyword>Pancreas Transplant</keyword>
	<keyword>Ganciclovir-resistance</keyword>
	<keyword>Valganciclovir</keyword>
	<keyword>CMV Disease</keyword>
</DOC>